 Comparison ribavirin placebo CDC group III human immunodeficiency virus infection Spanish Ribavirin Trial Group efficacy safety ribavirin patients human immunodeficiency virus HIV infection multicentre placebo-controlled trial CDC group III HIV-infected individuals February October treatment time weeks individuals treatment groups similar baseline subjects intravenous drug abuse main risk factor HIV infection Ribavirin dose mg/kg mouth average dose mg patients placebo group CDC Groups IVA ribavirin group Progressions group differences significant significant differences cell counts total lymphocytes total white cells ratios groups treatment important side-effects